This article is written live from the American Association of Clinical Endocrinologists (AACE) 2017 Annual Meeting in Austin, TX. MPR will be reporting news on the latest findings from leading experts in endocrinology. Check back for more news from AACE 2017.

According to findings of a post hoc analysis presented at the AACE 2017 Annual Meeting, canagliflozin (CANA) 300mg may positively affect cardiometabolic health by improving adipose tissue function in patients with type 2 diabetes mellitus (T2DM).

Both T2DM and obesity are known to be pro-inflammatory conditions that increase the risk of cardiovascular disease (CVD). Because of this, lead study author W. Timothy Garvey, MD, of the UAB Diabetes Research Center at the University of Alabama, in Birmingham, AL, and colleagues aimed to assess “the effects of CANA vs. GLIM [glimepiride] on select adipokines, inflammatory markers, and chemokines that have been associated with impaired adipose tissue function, insulin resistance, and CVD.”

To complete this task, the study authors utilized data from a recent Phase 3 trial which found CANA to be more effective at reducing A1c and body weight compared to GLIM. Serum samples of 200 randomly selected patients receiving CANA or GLIM were obtained from the original study. Changes in serum levels of leptin, adiponectin, CRP, PAI-1, VCAM-1, MCP-1, IL-6, and TNFa from baseline to week 52 were measured and reported.

The study authors found that “at week 52, the least squares mean (LSM) change in A1c was -0.99% with CANA and -0.91% with GLIM (BL=7.7–7.8%).” CANA was also found to be associated with a larger LSM change in body weight compared to GLIM (-4.1kg and 0.7kg, respectively).

Data obtained from the study also found that treatment with CANA decreased serum levels of leptin and IL-6 compared to GLIM (26% reduction for leptin, 23% reduction for IL-6). CANA was also associated with a 17% increase in levels of adiponectin and a 9% increase in TNFa levels vs. GLIM. The study authors noted that no differences were observed between the treatment groups for serum levels of CRP, PAI-1, VCAM-1, or MCP-1.

Analysis also found that “the CANA-related changes in leptin, adiponectin, and IL-6 were independent of glycemic benefit, and the changes in adiponectin and IL-6 were independent of weight loss.”

Findings of this post hoc analysis demonstrated that CANA is associated with a reduction in serum leptin and IL-6 levels as well as an increase in adiponectin and TNFa levels compared to GLIM. The study authors concluded, “these collective results suggest that CANA may improve adipose tissue function, which may have positive effects on cardiometabolic health.”

For continuous endocrine news coverage from the AACE 2017 Annual Meeting, check back to MPR’s AACE page for the latest updates.